Physician profile
Feng Ge
NPI 1922004803
$2,626.28
in general payments reported to CMS, 2019-2025
32 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,827 · 2020: $457 · 2021: $26.42 · 2023: $39.07 · 2024: $147 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $316.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $636.45 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.55 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $223.33 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $202.68 | 2019-2020 | |
| Abbvie INC. | $188.84 | 2019-2020 | |
| Horizon Therapeutics Plc | $129.01 | 2019-2020 | |
| Amgen INC. | $114.47 | 2019-2020 | |
| Astellas Pharma US INC | $114.13 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $105.36 | 2019-2025 | Capvaxive, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $86.97 | 2019-2020 | |
| Antares Pharma, INC. | $64.89 | 2019 | |
| Glaxosmithkline, LLC. | $57.74 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $47.33 | 2019-2020 | |
| Radius Health, INC. | $42.99 | 2019-2020 | |
| Sanofi Pasteur INC. | $39.48 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $36.61 | 2024-2025 | Inspire |
| Madrigal Pharmaceuticals | $36.27 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $31.15 | 2019 | |
| Genentech USA, INC. | $30.71 | 2019-2020 | |
| Lundbeck LLC | $25.48 | 2023 | Vyepti |
| Hikma Pharmaceuticals USA | $24.12 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $22.09 | 2020 | |
| Resmed Corp | $18.68 | 2024 | |
| Ibsa Pharma INC. | $18.60 | 2020 | |
| Sobi, INC | $17.59 | 2019 | |
| Shire North American Group INC | $15.83 | 2019 | |
| Lilly USA, LLC | $14.18 | 2025 | Zepbound |
| Novo Nordisk INC | $13.59 | 2023 | Wegovy |
| Alexion Pharmaceuticals, INC. | $12.28 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.67 | 2019 | |
| Valeritas, INC. | $11.15 | 2019 | |
| Dynavax Technologies Corporation | $9.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Feng Ge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.